OACM5.1 C
OACM5.1 C
Cell Line Name
Cell Line Description
OACM5.1 C was established from a lymph node metastasis derived from a. primary adenocarcinoma of distal esophagus with the presence of Barretts transformed mucosa. The patient was a 47 year-old Caucasian female and exhibited lymph node involvement and distant pleural metastases. OACM5.1 C was found to be tumourigenic in NMRI (female nude mice or NOD-SCID miceCultures derived from ECACC stocks of this cell line have been whole genome sequenced (Contino et al 2016) confirming the presence of many of the known mutations that drive oesophageal cancer
General Info
Species
Human
Links
Cellosaurus: CVCL_1842
Release Conditions
Characteristics
Receptors
Products
Tissue of Origin
Morphology
DNA profile (STR Profile)
Amelogenin: X
CSF1PO: 10,13
D5S818: 11,12
D7S820: 8.2
D13S317: 11,12
D16S539: 10,11
TH01: 6,9.3
TPOX: 8
vWA: 19,20
Karyotype
Disease
Culture Conditions
Cell Type
Subculture Routine
Split sub-confluent cultures (70-80%) 1:4 to 1:10 i.e. seeding at 3 x 10,000 cells/cm² using 0.05% trypsin or trypsin/EDTA; 5% CO₂; 37°C.
Culture Medium
RPMI-1640 + 2mM Glutamine + 10% Foetal Bovine Serum (FBS)
Growth Mode
Additional Info
Depositor
Country of Origin
Hazard Group (ACDP)
Applications
References
Boonstra JJ, van Marion R, Beer DG, Lin L, Chaves P, Ribeiro C, Pereira AD, Roque L, Darnton SJ, Altorki NK, Schrump DS, Klimstra DS, Tang LH, Eshleman JR, Alvarez H, Shimada Y, van Dekken H, Tilanus HW, Dinjens WN. 2010 Verification and unmasking of widely used human esophageal adenocarcinoma cell lines. J Natl Cancer Inst. 102(4):271-4.PMID: 20075370.Whole-genome sequencing of nine esophageal adenocarcinoma cell lines
Bibliography
de Both NJ, Wijnhoven BP, Sleddens HF, Tilanus HW, Dinjens WN. 2001 Establishment of cell lines from adenocarcinomas of the esophagus and gastric cardia growing in vivo and in vitro. Virchows Arch. 438(5):451-6 PMID:11407472 Rosenberg C, Geelen E, IJszenga MJ, Pearson P, Tanke HJ, Dinjens WN, van Dekken H. 2002 Spectrum of genetic changes in gastro-esophageal cancer cell lines determined by an integrated molecular cytogenetic approach. Cancer Genet Cytogenet. 135(1):35-41 PMID: 12072201. van Dekken H, Geelen E, Dinjens WN, Wijnhoven BP, Tilanus HW, Tanke HJ, Rosenberg C. 1999 Comparative genomic hybridization of cancer of the gastroesophageal junction: deletion of 14Q31-32.1 discriminates between esophageal (Barrett's) and gastric cardia adenocarcinomas. Cancer Res. 59(3):748-52. PMID: 9973227.
Available Formats
- Frozen
- DNA-5µg (100ng/µl)
Citation Guidance
If use of this culture results in a scientific publication, it should be cited in the publication as: OACM5.1 C (ECACC 11012006).
Biosafety Information
Unless specified otherwise, at ECACC we routinely handle all of our cell lines at containment level 2 in accordance with the ACDP guidelines (Advisory Committee on Dangerous Pathogens) (UK). All cell cultures have the potential to carry as yet unidentified adventitious agents. It is the responsibility of the end user to ensure that their facilities comply with biosafety regulations for their own country. ACDP Guidance: Biological agents: Managing the risks in laboratories and healthcare premises.
Further Information
The Culture Collections represent deposits of cultures from world-wide sources. While every effort is made to ensure details distributed by Culture Collections are accurate, Culture Collections cannot be held responsible for any inaccuracies in the data supplied. References where quoted are mainly attributed to the establishment of the cell culture and not for any specific property of the cell line, therefore further references should be obtained regarding cell culture characteristics. Passage numbers where given act only as a guide and Culture Collections does not guarantee the passage number stated will be the passage number received by the customer.
Cultures supplied by Culture Collections are for research purposes only. Enquiries regarding the commercial use of a cell line are referred to the depositor of the cell line. Some cell lines have additional special release conditions such as the requirement for a material transfer agreement to be completed by the potential recipient prior to the supply of the cell line. Please view the Terms & Conditions of Supply for more information.